Drug – bio-affecting and body treating compositions – In vivo diagnosis or in vivo testing
Reexamination Certificate
2004-04-28
2009-10-13
Russel, Jeffrey E (Department: 1654)
Drug, bio-affecting and body treating compositions
In vivo diagnosis or in vivo testing
C424S009400, C530S330000
Reexamination Certificate
active
07601333
ABSTRACT:
The invention concerns the use of ACE-resistant N-acétyl-Ser-Asp-Lys-Pro analogues for preparing a reagent or marker adapted to measure a glomerular filtration rate.
REFERENCES:
Junot, Christophe et al.: “Development of an enzyme immunoassay for a stable amidated analog of the hemoregulatory Peptide Acetyl-Ser-Asp-Lys-Pro”, Journal of Immunoassay and Immunochemistry, vol. 22, No. 1, pp. 15-31, 2001.
Gaudron, Sandrine et al: “NAcSDKP Analogues Resistant to Angiotensin-Converting Enzyme”, Journal of Medicinal Chemistry, vol. 40, pp. 3963-3968, 1997.
Azizi, Michel et al: “Renal and Metabolic Clearance of N-acetyl-seryl-aspartyl-lysyl-proline (AcSDKP) during angiotensin-converting enzyme Inhibition in humans”, Hypertension (Baltimore), vol. 33, No. 3, pp. 879-886, 1999.
Azizi Michel
Ezan Eric
Assistance Publique-Hopitaux de Paris
Commissariat a l''Energie Atomique
Oblon, Spivak McClelland, Maier & Neustadt, L.L.P.
Russel Jeffrey E
LandOfFree
Use of a tetrapeptide AcSDKP (SEQ ID No. 1) analog resistant... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of a tetrapeptide AcSDKP (SEQ ID No. 1) analog resistant..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of a tetrapeptide AcSDKP (SEQ ID No. 1) analog resistant... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4134382